Anthropic rings the Nasdaq bell and then solves Riemann Hypothesis, what next now?
Anthropic (ANT) debuted on Nasdaq with a $1.5T market cap, briefly surpassing $2T before a selloff. The company aims to focus on institutional AI applications, particularly in medicine, and claims to have solved the Riemann Hypothesis. However, it faces challenges in justifying its valuation, with projected 2026 revenue of $45B falling short of the $600B needed for 20% returns on $1T AI investment. Sarvam, an Indian AI company, pivoted to offering inference services, sparking debate.
How this was made

The 30-second read
Why it matters
The IPO creates immediate trading opportunities, while the Riemann claim could boost long‑term credibility but has no short‑term price effect.
Market read
A landmark AI IPO with massive valuation and early profit‑taking, generating short‑term trading focus.
What to watch
Potential regulatory scrutiny of AI applications and the need for sustained revenue growth beyond $45B in 2026.
Background
Anthropic, a leading AI model developer, completed a high‑profile Nasdaq debut and claimed a breakthrough in solving the Riemann Hypothesis.
Ticker impact
Anthropic's IPO debuted with a $1.5T market cap, surged past $2T, then slid as investors booked profits.
likely downward pressure as investors sell after the initial surge
The article reports a fresh IPO and immediate sell‑off, a primary market‑moving event with large valuation.
Market effects
Highlights the volatility of large‑cap AI IPOs and may temper enthusiasm for similar listings.
US tech market focus; limited immediate effect outside North America.
Sets a benchmark for AI valuations worldwide, but impact confined to equity markets.
Counterpoint
The hype around the IPO may be overstated; the rapid profit‑taking suggests the valuation is unsustainable.
Key entities
- CompanyAnthropic
AI model developer that went public on Nasdaq.



